U.S. SENATE,
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C., May 27, 1975.

NEIL L. CHAYET, *Esq.*,
Chayet and Sonnenreich, P.C.
Boston, Mass.

DEAR MR. CHAYET: This is in response to your letter of February 14, 1975 accompanied by your correspondence with Commissioner Schmidt of the Food and Drug Administration, as well as your prior phone request to me.

It is true that our Monopoly Subcommittee plans to hold another hearing on the oral hypoglycemic drugs, at which time the FDA will testify on labeling changes. Although your request to appear once again before the Subcommittee is appreciated, this will not be necessary since your position is already part of the hearing transcript. However, should you desire to place additional material into the record following the final testimony of the FDA, you may do so.

In the meantime, I should be extremely grateful if you would send us a complete list of members (and their addresses) of the Committee on the Care of the Diabetic, the organization you represent.

Your continued interest in the work of our Subcommittee is appreciated.

Sincerely,

BENJAMIN GORDON,
Staff Economist.

CHAYET AND SONNENREICH, P. C.,
ATTORNEYS AT LAW,
Boston, Mass., July 10, 1975.

MR. BENJAMIN GORDON,
Staff Economist,
U. S. Senate,
Select Committee on Small Business,
Washington, D.C.

DEAR MR. GORDON: I am in receipt of your recent letter referring the request of the Committee on the Care of the Diabetic (CCD) to testify before the Monopoly Subcommittee in the hearings held this week relative to labeling of oral hypoglycemic drugs.

As you know, CCD has been involved in the labeling controversy for several years, appearing before administrative, legislative, and judicial bodies. From the list of witnesses who appeared before the subcommittee, it would appear that the testimony offered this week represented only one side of the controversy.

Particularly in view of very recent developments in the controversy, i.e. the FDA's proposed relabeling of the drugs (Federal Register, Vol. 40, No. 130, pp 28582–28595), CCD regrets not having been permitted to testify, as its testimony could have availed the Subcommittee of a more balanced view of the issues.

I am enclosing, per your request, a list of CCD members. Kindly include this letter on the record of the proceedings.

Very truly yours,

NEIL L. CHAYET.

Enclosure.

Frank N. Allan, Chairman Emeritus, Medical Department, Lahey Clinic, 44 Barnstable Road, West Newton, Massachusetts 02165.
Seymour Alterman, M.D., 1688 Meridan Avenue, Miami Beach, Florida 33139.
Shepard G. Aronson, M.D., 150 East 56th Street, New York, N. Y. 10022.
James B. Ashmore, M.D., Professor of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana.
Donald M. Barnard, M.D., Fargo Clinic, Fargo, N.D.
Donald Barnett, M.D., Joslin Clinic, 15 Joslin Road, Boston, Massachusetts 02215.
Samuel B. Beaser, M.D., 31 Bay State Road, Boston, Massachusetts.
Lewis H. Biben, M.D., 618 Medical Science Building, 916 Nineteenth Street, N.W., Washington, D. C. 20006.
Keith Borden, M.D., Chief, Diabetes Products, The Upjohn Company, Kalamazoo, Michigan 49001.
Angela Bowen, M.D., 1015 West 4th Street, Olympia, Washington 98501.
Robert F. Bradley, M.D., Medical Director, Joslin Clinic, 15 Joslin Road, Boston, Massachusetts 02215.